Carvedilol Achieves Higher Hemodynamic Response and Lower Rebleeding Rates Than Propranolol in Secondary Prophylaxis

Carvedilol induces stronger decreases in hepatic venous pressure gradient (HVPG) than conventional nonselective β-blockers (ie, propranolol). Limited data exist on the efficacy of carvedilol in secondary prophylaxis of variceal bleeding. Patients undergoing paired HVPG measurements for guiding secon...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical gastroenterology and hepatology 2023-08, Vol.21 (9), p.2318-2326.e7
Hauptverfasser: Jachs, Mathias, Hartl, Lukas, Simbrunner, Benedikt, Bauer, David, Paternostro, Rafael, Balcar, Lorenz, Hofer, Benedikt, Pfisterer, Nikolaus, Schwarz, Michael, Scheiner, Bernhard, Stättermayer, Albert F., Pinter, Matthias, Trauner, Michael, Mandorfer, Mattias, Reiberger, Thomas
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2326.e7
container_issue 9
container_start_page 2318
container_title Clinical gastroenterology and hepatology
container_volume 21
creator Jachs, Mathias
Hartl, Lukas
Simbrunner, Benedikt
Bauer, David
Paternostro, Rafael
Balcar, Lorenz
Hofer, Benedikt
Pfisterer, Nikolaus
Schwarz, Michael
Scheiner, Bernhard
Stättermayer, Albert F.
Pinter, Matthias
Trauner, Michael
Mandorfer, Mattias
Reiberger, Thomas
description Carvedilol induces stronger decreases in hepatic venous pressure gradient (HVPG) than conventional nonselective β-blockers (ie, propranolol). Limited data exist on the efficacy of carvedilol in secondary prophylaxis of variceal bleeding. Patients undergoing paired HVPG measurements for guiding secondary prophylaxis with either carvedilol or propranolol were included in this retrospective analysis. All patients also underwent band ligation. Changes in HVPG and systemic hemodynamics were compared between the 2 groups. Long-term follow-up data on rebleeding, acute kidney injury, nonbleeding decompensation, and liver-related death were analyzed applying competing risk regression. Eighty-seven patients (carvedilol/propranolol, n = 45/42) were included in our study. The median baseline HVPG was 21 mm Hg (interquartile range, 18–24 mm Hg), and 39.1%/48.3%/12.6% had Child–Turcotte–Pugh A/B/C cirrhosis, respectively. Upon nonselective β-blocker initiation, HVPG decreased more strongly in carvedilol users (median relative decrease, -20% [interquartile range: -29% to -10%] vs -11% [-22% to -5%] for propranolol; P = .027), who also achieved chronic HVPG response more often (53.3% vs 28.6%; P = .034). Cumulative incidences for rebleeding (Gray test, P = .027) and liver-related death (P = .036) were significantly lower in patients taking carvedilol compared with propranolol. Notably, ascites development/worsening also was observed less commonly in carvedilol patients (P = .012). Meanwhile, acute kidney injury rates did not differ between the 2 groups (P = .255). Stratifying patients by HVPG response status yielded similar results. The prognostic value of carvedilol intake was confirmed in competing risk regression models. Carvedilol induces more marked reductions in HVPG than propranolol in secondary prophylaxis of variceal bleeding, and thus is associated with lower rates of rebleeding, liver-related death, and further nonbleeding decompensation. [Display omitted]
doi_str_mv 10.1016/j.cgh.2022.06.007
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2691051895</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1542356522006425</els_id><sourcerecordid>2691051895</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-d8efa0a2084ce2d537b9ece08f3e0da7c240ed53859f134efbea112f5577796b3</originalsourceid><addsrcrecordid>eNp9kEFv2zAMhYVhxdJm-wG7FDruEk-SLctGT0WwLgUCtEjTsyBLdKzAljLJyZp_P2XJduyJBPneA_kh9JWSjBJaft9metNljDCWkTIjRHxA15QXbCYELT5e-pyXfIJuYtwSwuqiFp_QJOdVwSitrtE4V-EAxva-x_e6s3CAiBd200HACxi8OTo1WI1XEHfeRcDKGbz0v9N6BU0Pyeo2eKXGZFt3yuHn4HdBOX8KtA6_gPbOqHD8u-iOvXqz8TO6alUf4culTtHrw4_1fDFbPv18nN8vZzqvy3FmKmgVUYxUhQZmeC6aGjSQqs2BGCU0KwikccXrluYFtA0oSlnLuRCiLpt8ir6dc3fB_9pDHOVgo4a-Vw78PkpW1pRwWtU8SelZqoOPMUArd8EO6W5JiTzBlluZYMsTbElKmWAnz-0lft8MYP47_tFNgruzANKTBwtBRm3B6QQtgB6l8fad-D_c1ZFi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2691051895</pqid></control><display><type>article</type><title>Carvedilol Achieves Higher Hemodynamic Response and Lower Rebleeding Rates Than Propranolol in Secondary Prophylaxis</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Jachs, Mathias ; Hartl, Lukas ; Simbrunner, Benedikt ; Bauer, David ; Paternostro, Rafael ; Balcar, Lorenz ; Hofer, Benedikt ; Pfisterer, Nikolaus ; Schwarz, Michael ; Scheiner, Bernhard ; Stättermayer, Albert F. ; Pinter, Matthias ; Trauner, Michael ; Mandorfer, Mattias ; Reiberger, Thomas</creator><creatorcontrib>Jachs, Mathias ; Hartl, Lukas ; Simbrunner, Benedikt ; Bauer, David ; Paternostro, Rafael ; Balcar, Lorenz ; Hofer, Benedikt ; Pfisterer, Nikolaus ; Schwarz, Michael ; Scheiner, Bernhard ; Stättermayer, Albert F. ; Pinter, Matthias ; Trauner, Michael ; Mandorfer, Mattias ; Reiberger, Thomas</creatorcontrib><description>Carvedilol induces stronger decreases in hepatic venous pressure gradient (HVPG) than conventional nonselective β-blockers (ie, propranolol). Limited data exist on the efficacy of carvedilol in secondary prophylaxis of variceal bleeding. Patients undergoing paired HVPG measurements for guiding secondary prophylaxis with either carvedilol or propranolol were included in this retrospective analysis. All patients also underwent band ligation. Changes in HVPG and systemic hemodynamics were compared between the 2 groups. Long-term follow-up data on rebleeding, acute kidney injury, nonbleeding decompensation, and liver-related death were analyzed applying competing risk regression. Eighty-seven patients (carvedilol/propranolol, n = 45/42) were included in our study. The median baseline HVPG was 21 mm Hg (interquartile range, 18–24 mm Hg), and 39.1%/48.3%/12.6% had Child–Turcotte–Pugh A/B/C cirrhosis, respectively. Upon nonselective β-blocker initiation, HVPG decreased more strongly in carvedilol users (median relative decrease, -20% [interquartile range: -29% to -10%] vs -11% [-22% to -5%] for propranolol; P = .027), who also achieved chronic HVPG response more often (53.3% vs 28.6%; P = .034). Cumulative incidences for rebleeding (Gray test, P = .027) and liver-related death (P = .036) were significantly lower in patients taking carvedilol compared with propranolol. Notably, ascites development/worsening also was observed less commonly in carvedilol patients (P = .012). Meanwhile, acute kidney injury rates did not differ between the 2 groups (P = .255). Stratifying patients by HVPG response status yielded similar results. The prognostic value of carvedilol intake was confirmed in competing risk regression models. Carvedilol induces more marked reductions in HVPG than propranolol in secondary prophylaxis of variceal bleeding, and thus is associated with lower rates of rebleeding, liver-related death, and further nonbleeding decompensation. [Display omitted]</description><identifier>ISSN: 1542-3565</identifier><identifier>EISSN: 1542-7714</identifier><identifier>DOI: 10.1016/j.cgh.2022.06.007</identifier><identifier>PMID: 35842118</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Cirrhosis ; Nonselective β-Blocker ; Portal Pressure ; Variceal Bleeding</subject><ispartof>Clinical gastroenterology and hepatology, 2023-08, Vol.21 (9), p.2318-2326.e7</ispartof><rights>2023 The Authors</rights><rights>Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-d8efa0a2084ce2d537b9ece08f3e0da7c240ed53859f134efbea112f5577796b3</citedby><cites>FETCH-LOGICAL-c396t-d8efa0a2084ce2d537b9ece08f3e0da7c240ed53859f134efbea112f5577796b3</cites><orcidid>0000-0002-4590-3583</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.cgh.2022.06.007$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35842118$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jachs, Mathias</creatorcontrib><creatorcontrib>Hartl, Lukas</creatorcontrib><creatorcontrib>Simbrunner, Benedikt</creatorcontrib><creatorcontrib>Bauer, David</creatorcontrib><creatorcontrib>Paternostro, Rafael</creatorcontrib><creatorcontrib>Balcar, Lorenz</creatorcontrib><creatorcontrib>Hofer, Benedikt</creatorcontrib><creatorcontrib>Pfisterer, Nikolaus</creatorcontrib><creatorcontrib>Schwarz, Michael</creatorcontrib><creatorcontrib>Scheiner, Bernhard</creatorcontrib><creatorcontrib>Stättermayer, Albert F.</creatorcontrib><creatorcontrib>Pinter, Matthias</creatorcontrib><creatorcontrib>Trauner, Michael</creatorcontrib><creatorcontrib>Mandorfer, Mattias</creatorcontrib><creatorcontrib>Reiberger, Thomas</creatorcontrib><title>Carvedilol Achieves Higher Hemodynamic Response and Lower Rebleeding Rates Than Propranolol in Secondary Prophylaxis</title><title>Clinical gastroenterology and hepatology</title><addtitle>Clin Gastroenterol Hepatol</addtitle><description>Carvedilol induces stronger decreases in hepatic venous pressure gradient (HVPG) than conventional nonselective β-blockers (ie, propranolol). Limited data exist on the efficacy of carvedilol in secondary prophylaxis of variceal bleeding. Patients undergoing paired HVPG measurements for guiding secondary prophylaxis with either carvedilol or propranolol were included in this retrospective analysis. All patients also underwent band ligation. Changes in HVPG and systemic hemodynamics were compared between the 2 groups. Long-term follow-up data on rebleeding, acute kidney injury, nonbleeding decompensation, and liver-related death were analyzed applying competing risk regression. Eighty-seven patients (carvedilol/propranolol, n = 45/42) were included in our study. The median baseline HVPG was 21 mm Hg (interquartile range, 18–24 mm Hg), and 39.1%/48.3%/12.6% had Child–Turcotte–Pugh A/B/C cirrhosis, respectively. Upon nonselective β-blocker initiation, HVPG decreased more strongly in carvedilol users (median relative decrease, -20% [interquartile range: -29% to -10%] vs -11% [-22% to -5%] for propranolol; P = .027), who also achieved chronic HVPG response more often (53.3% vs 28.6%; P = .034). Cumulative incidences for rebleeding (Gray test, P = .027) and liver-related death (P = .036) were significantly lower in patients taking carvedilol compared with propranolol. Notably, ascites development/worsening also was observed less commonly in carvedilol patients (P = .012). Meanwhile, acute kidney injury rates did not differ between the 2 groups (P = .255). Stratifying patients by HVPG response status yielded similar results. The prognostic value of carvedilol intake was confirmed in competing risk regression models. Carvedilol induces more marked reductions in HVPG than propranolol in secondary prophylaxis of variceal bleeding, and thus is associated with lower rates of rebleeding, liver-related death, and further nonbleeding decompensation. [Display omitted]</description><subject>Cirrhosis</subject><subject>Nonselective β-Blocker</subject><subject>Portal Pressure</subject><subject>Variceal Bleeding</subject><issn>1542-3565</issn><issn>1542-7714</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kEFv2zAMhYVhxdJm-wG7FDruEk-SLctGT0WwLgUCtEjTsyBLdKzAljLJyZp_P2XJduyJBPneA_kh9JWSjBJaft9metNljDCWkTIjRHxA15QXbCYELT5e-pyXfIJuYtwSwuqiFp_QJOdVwSitrtE4V-EAxva-x_e6s3CAiBd200HACxi8OTo1WI1XEHfeRcDKGbz0v9N6BU0Pyeo2eKXGZFt3yuHn4HdBOX8KtA6_gPbOqHD8u-iOvXqz8TO6alUf4culTtHrw4_1fDFbPv18nN8vZzqvy3FmKmgVUYxUhQZmeC6aGjSQqs2BGCU0KwikccXrluYFtA0oSlnLuRCiLpt8ir6dc3fB_9pDHOVgo4a-Vw78PkpW1pRwWtU8SelZqoOPMUArd8EO6W5JiTzBlluZYMsTbElKmWAnz-0lft8MYP47_tFNgruzANKTBwtBRm3B6QQtgB6l8fad-D_c1ZFi</recordid><startdate>202308</startdate><enddate>202308</enddate><creator>Jachs, Mathias</creator><creator>Hartl, Lukas</creator><creator>Simbrunner, Benedikt</creator><creator>Bauer, David</creator><creator>Paternostro, Rafael</creator><creator>Balcar, Lorenz</creator><creator>Hofer, Benedikt</creator><creator>Pfisterer, Nikolaus</creator><creator>Schwarz, Michael</creator><creator>Scheiner, Bernhard</creator><creator>Stättermayer, Albert F.</creator><creator>Pinter, Matthias</creator><creator>Trauner, Michael</creator><creator>Mandorfer, Mattias</creator><creator>Reiberger, Thomas</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4590-3583</orcidid></search><sort><creationdate>202308</creationdate><title>Carvedilol Achieves Higher Hemodynamic Response and Lower Rebleeding Rates Than Propranolol in Secondary Prophylaxis</title><author>Jachs, Mathias ; Hartl, Lukas ; Simbrunner, Benedikt ; Bauer, David ; Paternostro, Rafael ; Balcar, Lorenz ; Hofer, Benedikt ; Pfisterer, Nikolaus ; Schwarz, Michael ; Scheiner, Bernhard ; Stättermayer, Albert F. ; Pinter, Matthias ; Trauner, Michael ; Mandorfer, Mattias ; Reiberger, Thomas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-d8efa0a2084ce2d537b9ece08f3e0da7c240ed53859f134efbea112f5577796b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Cirrhosis</topic><topic>Nonselective β-Blocker</topic><topic>Portal Pressure</topic><topic>Variceal Bleeding</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jachs, Mathias</creatorcontrib><creatorcontrib>Hartl, Lukas</creatorcontrib><creatorcontrib>Simbrunner, Benedikt</creatorcontrib><creatorcontrib>Bauer, David</creatorcontrib><creatorcontrib>Paternostro, Rafael</creatorcontrib><creatorcontrib>Balcar, Lorenz</creatorcontrib><creatorcontrib>Hofer, Benedikt</creatorcontrib><creatorcontrib>Pfisterer, Nikolaus</creatorcontrib><creatorcontrib>Schwarz, Michael</creatorcontrib><creatorcontrib>Scheiner, Bernhard</creatorcontrib><creatorcontrib>Stättermayer, Albert F.</creatorcontrib><creatorcontrib>Pinter, Matthias</creatorcontrib><creatorcontrib>Trauner, Michael</creatorcontrib><creatorcontrib>Mandorfer, Mattias</creatorcontrib><creatorcontrib>Reiberger, Thomas</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jachs, Mathias</au><au>Hartl, Lukas</au><au>Simbrunner, Benedikt</au><au>Bauer, David</au><au>Paternostro, Rafael</au><au>Balcar, Lorenz</au><au>Hofer, Benedikt</au><au>Pfisterer, Nikolaus</au><au>Schwarz, Michael</au><au>Scheiner, Bernhard</au><au>Stättermayer, Albert F.</au><au>Pinter, Matthias</au><au>Trauner, Michael</au><au>Mandorfer, Mattias</au><au>Reiberger, Thomas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Carvedilol Achieves Higher Hemodynamic Response and Lower Rebleeding Rates Than Propranolol in Secondary Prophylaxis</atitle><jtitle>Clinical gastroenterology and hepatology</jtitle><addtitle>Clin Gastroenterol Hepatol</addtitle><date>2023-08</date><risdate>2023</risdate><volume>21</volume><issue>9</issue><spage>2318</spage><epage>2326.e7</epage><pages>2318-2326.e7</pages><issn>1542-3565</issn><eissn>1542-7714</eissn><abstract>Carvedilol induces stronger decreases in hepatic venous pressure gradient (HVPG) than conventional nonselective β-blockers (ie, propranolol). Limited data exist on the efficacy of carvedilol in secondary prophylaxis of variceal bleeding. Patients undergoing paired HVPG measurements for guiding secondary prophylaxis with either carvedilol or propranolol were included in this retrospective analysis. All patients also underwent band ligation. Changes in HVPG and systemic hemodynamics were compared between the 2 groups. Long-term follow-up data on rebleeding, acute kidney injury, nonbleeding decompensation, and liver-related death were analyzed applying competing risk regression. Eighty-seven patients (carvedilol/propranolol, n = 45/42) were included in our study. The median baseline HVPG was 21 mm Hg (interquartile range, 18–24 mm Hg), and 39.1%/48.3%/12.6% had Child–Turcotte–Pugh A/B/C cirrhosis, respectively. Upon nonselective β-blocker initiation, HVPG decreased more strongly in carvedilol users (median relative decrease, -20% [interquartile range: -29% to -10%] vs -11% [-22% to -5%] for propranolol; P = .027), who also achieved chronic HVPG response more often (53.3% vs 28.6%; P = .034). Cumulative incidences for rebleeding (Gray test, P = .027) and liver-related death (P = .036) were significantly lower in patients taking carvedilol compared with propranolol. Notably, ascites development/worsening also was observed less commonly in carvedilol patients (P = .012). Meanwhile, acute kidney injury rates did not differ between the 2 groups (P = .255). Stratifying patients by HVPG response status yielded similar results. The prognostic value of carvedilol intake was confirmed in competing risk regression models. Carvedilol induces more marked reductions in HVPG than propranolol in secondary prophylaxis of variceal bleeding, and thus is associated with lower rates of rebleeding, liver-related death, and further nonbleeding decompensation. [Display omitted]</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35842118</pmid><doi>10.1016/j.cgh.2022.06.007</doi><orcidid>https://orcid.org/0000-0002-4590-3583</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1542-3565
ispartof Clinical gastroenterology and hepatology, 2023-08, Vol.21 (9), p.2318-2326.e7
issn 1542-3565
1542-7714
language eng
recordid cdi_proquest_miscellaneous_2691051895
source Elsevier ScienceDirect Journals Complete
subjects Cirrhosis
Nonselective β-Blocker
Portal Pressure
Variceal Bleeding
title Carvedilol Achieves Higher Hemodynamic Response and Lower Rebleeding Rates Than Propranolol in Secondary Prophylaxis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T21%3A29%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Carvedilol%20Achieves%20Higher%20Hemodynamic%20Response%20and%20Lower%20Rebleeding%20Rates%20Than%20Propranolol%20in%20Secondary%20Prophylaxis&rft.jtitle=Clinical%20gastroenterology%20and%20hepatology&rft.au=Jachs,%20Mathias&rft.date=2023-08&rft.volume=21&rft.issue=9&rft.spage=2318&rft.epage=2326.e7&rft.pages=2318-2326.e7&rft.issn=1542-3565&rft.eissn=1542-7714&rft_id=info:doi/10.1016/j.cgh.2022.06.007&rft_dat=%3Cproquest_cross%3E2691051895%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2691051895&rft_id=info:pmid/35842118&rft_els_id=S1542356522006425&rfr_iscdi=true